Evidence map›Paper›PMID 38791146›Full record

ArticleInternational journal of molecular sciences2024

Multi-Omics Characterization of Colon Mucosa and Submucosa/Wall from Crohn's Disease Patients.

Liang Jin, Michael Macoritto, Jing Wang, Yingtao Bi, Fei Wang, Abel Suarez-Fueyo, Jesus Paez-Cortez, Chenqi Hu, Heather Knight, Ivan Mascanfroni and 5 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Frontiers in immunology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Liang JinAbbVie Bioresearch Center, Worcester, MA 01605, USA.
Michael MacorittoImmunology Research, AbbVie, Cambridge, MA 02139, USA.
Jing WangImmunology Research, AbbVie, Cambridge, MA 02139, USA.
Yingtao BiAbbVie Bioresearch Center, Worcester, MA 01605, USA.
Fei WangAbbVie Bioresearch Center, Worcester, MA 01605, USA.
Abel Suarez-FueyoImmunology Research, AbbVie, Cambridge, MA 02139, USA.ORCID 0000-0002-8696-0197
Jesus Paez-CortezVertex Pharmaceuticals, Boston, MA 02210, USA.
Chenqi HuAlnylam Pharmaceuticals, Cambridge, MA 02139, USA.
Heather KnightAbbVie Bioresearch Center, Worcester, MA 01605, USA.
Ivan MascanfroniSeismic Therapeutic, Watertown, MA 02472, USA.
Matthew M StaronAbbVie Bioresearch Center, Worcester, MA 01605, USA.
Annette Schwartz StermanAbbVie Bioresearch Center, Worcester, MA 01605, USA.
Jean Marie HoughtonDivision of Gastroenterology, Department of Medicine, UMass Chan Medical School, Worcester, MA 01655, USA.
Susan WestmorelandAbbVie Bioresearch Center, Worcester, MA 01605, USA.
Yu TianAbbVie Bioresearch Center, Worcester, MA 01605, USA.ORCID 0000-0003-3754-5875

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Crohn's disease (CD) is a subtype of inflammatory bowel disease (IBD) characterized by transmural disease. The concept of transmural healing (TH) has been proposed as an indicator of deep clinical remission of CD and as a predictor of favorable treatment endpoints. Understanding the pathophysiology involved in transmural disease is critical to achieving these endpoints. However, most studies have focused on the intestinal mucosa, overlooking the contribution of the intestinal wall in Crohn's disease. Multi-omics approaches have provided new avenues for exploring the pathogenesis of Crohn's disease and identifying potential biomarkers. We aimed to use transcriptomic and proteomic technologies to compare immune and mesenchymal cell profiles and pathways in the mucosal and submucosa/wall compartments to better understand chronic refractory disease elements to achieve transmural healing. The results revealed similarities and differences in gene and protein expression profiles, metabolic mechanisms, and immune and non-immune pathways between these two compartments. Additionally, the identification of protein isoforms highlights the complex molecular mechanisms underlying this disease, such as decreased RTN4 isoforms (RTN4B2 and RTN4C) in the submucosa/wall, which may be related to the dysregulation of enteric neural processes. These findings have the potential to inform the development of novel therapeutic strategies to achieve TH.

Indexed as

ColonCrohn DiseaseIntestinal MucosaProteomicsAdultBiomarkersFemaleGene Expression ProfilingHumansMaleMiddle AgedMultiomicsTranscriptomeBiomarkerscolonCrohn’s diseasehistologyisoformmucosaproteomicssubmucosatranscriptomicstransmural healingwall

Identifiers

PMID38791146
PMCPMC11121447

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.